In a patient with chronic persistent atrial fibrillation and heart failure with reduced ejection fraction who has been taking empagliflozin (Jardiance) for six months and has an NT‑proBNP of 1231 pg/mL, what is the recommended management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Persistent Atrial Fibrillation and HFrEF with Elevated NT-proBNP Despite SGLT2i Therapy

Continue empagliflozin (Jardiance) and optimize guideline-directed medical therapy (GDMT) by ensuring the patient is on maximal tolerated doses of ACE-I/ARB/ARNI, beta-blocker, and mineralocorticoid receptor antagonist (MRA), as this combination reduces mortality and hospitalization in HFrEF regardless of atrial fibrillation status. 1

Immediate Medication Optimization

Your patient's NT-proBNP of 1231 pg/mL after 6 months on empagliflozin indicates persistent symptomatic heart failure requiring intensification of therapy:

Core GDMT Components (Class I Recommendations)

  • ACE-I/ARB or ARNI: If on ACE-I/ARB and still symptomatic, strongly consider switching to sacubitril/valsartan, which provides additional mortality and hospitalization benefit beyond ACE-I alone 1

  • Beta-blocker: Ensure evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol) is uptitrated to target or maximally tolerated dose 1

  • MRA (spironolactone or eplerenone): Add if not already prescribed, as this reduces mortality in symptomatic HFrEF 1

  • Continue empagliflozin: The SGLT2i benefit persists regardless of atrial fibrillation status, with consistent reductions in cardiovascular death and HF hospitalization 2, 3, 4

Atrial Fibrillation Rate Control Strategy

For persistent AF with HFrEF, prioritize rate control using beta-blockers as first-line therapy, with digoxin as reasonable add-on therapy if rate control remains inadequate. 5, 6, 5

Rate Control Approach:

  • Beta-blocker is the preferred agent for rate control in HFrEF with AF (Class I recommendation) 5, 6, 5
  • Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil) as they worsen HF and increase hospitalization risk in HFrEF (Class III: Harm) 1
  • Add digoxin if beta-blocker alone provides insufficient rate control (Class IIa) 5, 6, 5
  • Assess exercise heart rate control and adjust medications to maintain physiological range during activity (Class I) 5, 6

Consider Rhythm Control:

If the patient remains symptomatic despite optimal rate control and GDMT, consider a rhythm-control strategy (cardioversion ± antiarrhythmic drugs or catheter ablation), as this is reasonable for chronic HF patients who remain symptomatic despite rate control (Class IIa) 5, 6, 5

Recent evidence suggests electrogram-anatomic guided catheter ablation provides superior long-term rhythm control and reduces cardiovascular events in persistent AF with HF 7

Prognostic Interpretation of NT-proBNP

An NT-proBNP of 1231 pg/mL indicates moderate-to-high residual risk despite SGLT2i therapy:

  • NT-proBNP levels between 125-1000 pg/mL are associated with incremental risk, and your patient's level of 1231 pg/mL portends meaningful ongoing risk of HF hospitalization and death 8
  • NT-proBNP offers much greater prognostic value than LVEF alone in patients on GDMT, making it the superior marker for risk stratification 8
  • Empagliflozin reduces NT-proBNP levels over time, but persistent elevation signals need for further therapy optimization 9, 4

Additional Considerations

Anticoagulation:

Ensure appropriate oral anticoagulation for stroke prevention given chronic persistent AF (Class I recommendation) 10

Diuretic Management:

Optimize loop diuretic dosing based on volume status—diuretics improve symptoms and exercise capacity in congested patients (Class I) 1

Device Therapy Evaluation:

If LVEF remains ≤35% after ≥3 months of optimal medical therapy, evaluate for ICD and/or CRT eligibility based on QRS duration and morphology 1

Common Pitfalls to Avoid

  1. Do not discontinue empagliflozin based on elevated NT-proBNP alone—the drug provides consistent benefit in HFrEF with AF 3
  2. Do not use calcium channel blockers for rate control in HFrEF—they cause harm 1
  3. Do not accept suboptimal GDMT dosing—uptitrate all four medication classes (ARNI/ACE-I, beta-blocker, MRA, SGLT2i) to target doses
  4. Do not overlook rhythm control if symptoms persist despite adequate rate control and optimized GDMT 5, 6, 5

References

Related Questions

Why is NT‑proBNP elevated in a patient with chronic persistent atrial fibrillation and heart failure with reduced ejection fraction who is on empagliflozin?
How should I risk‑stratify a patient with chronic persistent atrial fibrillation and heart failure with reduced ejection fraction who has an NT‑proBNP of 1,230 pg/mL?
What are the benefits of initiating empagliflozin (10 mg) once daily in a patient with chronic heart failure (reduced or preserved ejection fraction) who does not have type 1 diabetes, active ketoacidosis, or an eGFR < 30 mL/min/1.73 m²?
What are the recommended immediate management steps for a 57-year-old male with heart failure with reduced ejection fraction, a functioning implanted cardioverter‑defibrillator, coronary artery disease, hyperlipidemia, hypertension, who presents with dyspnea and white frothy sputum and a low B‑type natriuretic peptide?
What is the recommended guideline‑directed medical therapy for a patient with mildly reduced left ventricular ejection fraction (40‑45 %) and the following echocardiographic findings: moderate concentric left ventricular hypertrophy, inferior and inferolateral wall hypokinesis, Grade I diastolic dysfunction, severely dilated left atrium, calcific aortic valve without stenosis or regurgitation, mild mitral stenosis and regurgitation, and trace tricuspid regurgitation?
In a patient with metastatic gastric gastrointestinal stromal tumor (GIST) to the liver who progressed after first-line sunitinib following an initial 400 mg imatinib regimen, can imatinib be re‑induced at 800 mg as second-line therapy?
What mean arterial pressure (MAP) should be targeted in a septic shock patient with chronic hypertension?
What is the appropriate evaluation and management for an asymptomatic patient with alanine aminotransferase (ALT) levels 12 times the upper limit of normal?
Why is NT‑proBNP elevated in a patient with chronic persistent atrial fibrillation and heart failure with reduced ejection fraction who is on empagliflozin?
Can ceftriaxone be used together with metronidazole safely?
What are the guideline‑recommended in‑hospital treatment duration and therapeutic regimen for a femoropopliteal deep vein thrombosis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.